GW Pharmaceuticals Announces Preliminary Topline Results from Phase 2a Ulcerative Colitis Trial
News, Ulcerative colitis
GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing new therapeutics from its cannabinoid product platform and that commercialized the world’s first plant-derived cannabinoid prescription drug Sativex® ... Read more